Targeted therapies in the management of renal cell carcinoma: role of bevacizumab

Review

(2641) Views  (492) Full article downloads

Authors: Bernard Escudier, Jan Cosaert, Sangeeta Jethwa

Published Date September 2008 Volume 2008:2(3) Pages 517 - 530

DOI: http://dx.doi.org/10.2147/BTT.S3509

Bernard Escudier¹, Jan Cosaert², Sangeeta Jethwa²

¹Unité Immunothérapie, Institut Gustave Roussy, Villejuif, France; ²F. Hoffmann-La Roche Ltd, Basel, Switzerland

Abstract: Bevacizumab (10 mg/kg every 2 weeks), in combination with interferon alpha-2a (IFN), is an effective option for first-line therapy for advanced and/or metastatic renal cell carcinoma (RCC). Two phase III trials clearly show significant improvements in progression-free survival and response rate in patients with treatment-naïve metastatic RCC receiving bevacizumab combined with IFN compared with IFN. The dose of IFN, which was initiated at 9 MIU 3 times a week in these trials, can be reduced to effectively manage IFN-related side effects without compromising the efficacy of bevacizumab plus IFN. Bevacizumab has good tolerability with manageable side effects, both alone and in combination with other agents; the tolerability profile of bevacizumab in combination with IFN is consistent with the well-characterized and well-established profiles of these therapies. The tolerability of bevacizumab combined with IFN and the flexibility to manage IFN-related side effects are important considerations when selecting first-line therapy. With a number of options now available for RCC therapy, optimizing their use is a key consideration in improving patient benefit.

Keywords: bevacizumab (Avastin^®), interferon alpha, efficacy, tolerability, renal cell carcinoma (RCC), low-dose interferon